504 related articles for article (PubMed ID: 22525082)
1. Enhanced systemic exposure of fexofenadine via the intranasal administration of chitosan-coated liposome.
Qiang F; Shin HJ; Lee BJ; Han HK
Int J Pharm; 2012 Jul; 430(1-2):161-6. PubMed ID: 22525082
[TBL] [Abstract][Full Text] [Related]
2. Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system.
Han HK; Shin HJ; Ha DH
Eur J Pharm Sci; 2012 Aug; 46(5):500-7. PubMed ID: 22522117
[TBL] [Abstract][Full Text] [Related]
3. Preparation and evaluation of fexofenadine microemulsions for intranasal delivery.
Piao HM; Balakrishnan P; Cho HJ; Kim H; Kim YS; Chung SJ; Shim CK; Kim DD
Int J Pharm; 2010 Aug; 395(1-2):309-16. PubMed ID: 20635476
[TBL] [Abstract][Full Text] [Related]
4. Effect of piperine, a major component of black pepper, on the intestinal absorption of fexofenadine and its implication on food-drug interaction.
Jin MJ; Han HK
J Food Sci; 2010 Apr; 75(3):H93-6. PubMed ID: 20492299
[TBL] [Abstract][Full Text] [Related]
5. Poloxamer/cyclodextrin/chitosan-based thermoreversible gel for intranasal delivery of fexofenadine hydrochloride.
Cho HJ; Balakrishnan P; Park EK; Song KW; Hong SS; Jang TY; Kim KS; Chung SJ; Shim CK; Kim DD
J Pharm Sci; 2011 Feb; 100(2):681-91. PubMed ID: 20803575
[TBL] [Abstract][Full Text] [Related]
6. Effect of intestinal first-pass hydrolysis on the oral bioavailability of an ester prodrug of fexofenadine.
Ohura K; Soejima T; Nogata R; Adachi Y; Ninomiya S; Imai T
J Pharm Sci; 2012 Sep; 101(9):3264-74. PubMed ID: 22628163
[TBL] [Abstract][Full Text] [Related]
7. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
8. TPGS-chitosome as an effective oral delivery system for improving the bioavailability of Coenzyme Q10.
Shao Y; Yang L; Han HK
Eur J Pharm Biopharm; 2015 Jan; 89():339-46. PubMed ID: 25542680
[TBL] [Abstract][Full Text] [Related]
9. [Studies on preparation of recombinant hirudin-2 liposome and its pharmacokinetics by nasal delivery in rats].
Zhang YJ; Wang XL; Wu JM; Cheng MX
Zhongguo Zhong Yao Za Zhi; 2007 May; 32(9):801-4. PubMed ID: 17639978
[TBL] [Abstract][Full Text] [Related]
10. Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride.
Huh Y; Cho HJ; Yoon IS; Choi MK; Kim JS; Oh E; Chung SJ; Shim CK; Kim DD
Eur J Pharm Sci; 2010 Apr; 40(1):9-15. PubMed ID: 20149868
[TBL] [Abstract][Full Text] [Related]
11. [Studies on the insulin-liposomes double-coated by chitosan and chitosan-EDTA conjugates].
Wu ZH; Ping QN; Song YM; Lei XM; Li JY; Cai P
Yao Xue Xue Bao; 2004 Nov; 39(11):933-8. PubMed ID: 15696937
[TBL] [Abstract][Full Text] [Related]
12. Chitosan nanoconstructs for improved oral delivery of low molecular weight heparin: In vitro and in vivo evaluation.
Paliwal R; Paliwal SR; Agrawal GP; Vyas SP
Int J Pharm; 2012 Jan; 422(1-2):179-84. PubMed ID: 22079712
[TBL] [Abstract][Full Text] [Related]
13. Enhanced oral bioavailability of novel mucoadhesive pellets containing valsartan prepared by a dry powder-coating technique.
Cao QR; Liu Y; Xu WJ; Lee BJ; Yang M; Cui JH
Int J Pharm; 2012 Sep; 434(1-2):325-33. PubMed ID: 22688251
[TBL] [Abstract][Full Text] [Related]
14. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery.
Li N; Zhuang C; Wang M; Sun X; Nie S; Pan W
Int J Pharm; 2009 Sep; 379(1):131-8. PubMed ID: 19559775
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs.
Takeuchi H; Matsui Y; Sugihara H; Yamamoto H; Kawashima Y
Int J Pharm; 2005 Oct; 303(1-2):160-70. PubMed ID: 16125348
[TBL] [Abstract][Full Text] [Related]
16. Carbopol-incorporated thermoreversible gel for intranasal drug delivery.
Balakrishnan P; Park EK; Song CK; Ko HJ; Hahn TW; Song KW; Cho HJ
Molecules; 2015 Mar; 20(3):4124-35. PubMed ID: 25749681
[TBL] [Abstract][Full Text] [Related]
17. Formation of biopolymer-coated liposomes by electrostatic deposition of chitosan.
Laye C; McClements DJ; Weiss J
J Food Sci; 2008 Jun; 73(5):N7-15. PubMed ID: 18577008
[TBL] [Abstract][Full Text] [Related]
18. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine.
Uno T; Shimizu M; Sugawara K; Tateishi T
Drug Metab Dispos; 2006 Nov; 34(11):1875-9. PubMed ID: 16928786
[TBL] [Abstract][Full Text] [Related]
19. The use of chitosan-6-mercaptonicotinic acid nanoparticles for oral peptide drug delivery.
Millotti G; Perera G; Vigl C; Pickl K; Sinner FM; Bernkop-Schnürch A
Drug Deliv; 2011 Apr; 18(3):190-7. PubMed ID: 21039318
[TBL] [Abstract][Full Text] [Related]
20. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: a novel strategy to avoid intraduodenal administration.
Venishetty VK; Chede R; Komuravelli R; Adepu L; Sistla R; Diwan PV
Colloids Surf B Biointerfaces; 2012 Jun; 95():1-9. PubMed ID: 22463845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
